Stereotactic radiosurgery for ablation of ventricular tachycardia.


Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
01 Jul 2019
Historique:
received: 27 12 2018
accepted: 16 04 2019
pubmed: 24 5 2019
medline: 3 11 2020
entrez: 24 5 2019
Statut: ppublish

Résumé

Stereotactic body radiotherapy (SBRT) for ventricular tachycardias (VTs) could be an option after failed catheter ablation. In this study, we analysed the long-term efficacy and toxicity of SBRT applied as a bail-out procedure. Patients with structural heart disease and unsuccessful catheter ablations for VTs underwent SBRT. The planning target volume (PTV) was accurately delineated using exported 3D electroanatomical maps with the delineated critical part of re-entry circuits. This was defined by detailed electroanatomic mapping and by pacing manoeuvres during the procedure. Using the implantable cardioverter-defibrillator lead as a surrogate contrast marker for respiratory movement compensation, 25 Gy was delivered to the PTV using CyberKnife. We evaluated occurrences of sustained VT, electrical storm, antitachycardia pacing, and shock; time to death; and radiation-induced events. From 2014 until March 2017, 10 patients underwent radiosurgical ablation (mean PTV, 22.15 mL; treatment duration, 68 min). After radiosurgery, four patients experienced nausea and one patient presented gradual progression of mitral regurgitation. During the follow-up (median 28 months), VT burden was reduced by 87.5% compared with baseline (P = 0.012) and three patients suffered non-arrhythmic deaths. After the blanking period, VT recurred in eight of 10 patients. The mean time to first antitachycardia pacing and shock were 6.5 and 21 months, respectively. Stereotactic body radiotherapy appears to show long-term safety and effectiveness for VT ablation in structural heart disease inaccessible to catheter ablation. We report one possible radiation-related toxicity and promising overall survival, warranting evaluation in a prospective multicentre clinical trial.

Identifiants

pubmed: 31121018
pii: 5497839
doi: 10.1093/europace/euz133
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1088-1095

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Radek Neuwirth (R)

Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Jakub Cvek (J)

Department of Oncology, University Hospital Ostrava, 17. listopadu 1790, Ostrava, Czech Republic.

Lukas Knybel (L)

Department of Oncology, University Hospital Ostrava, 17. listopadu 1790, Ostrava, Czech Republic.

Otakar Jiravsky (O)

Cardiology, Podlesi Hospital Trinec, Czech Republic.

Lukas Molenda (L)

Department of Oncology, University Hospital Ostrava, 17. listopadu 1790, Ostrava, Czech Republic.

Michal Kodaj (M)

Cardiology, Podlesi Hospital Trinec, Czech Republic.

Martin Fiala (M)

Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Petr Peichl (P)

Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

David Feltl (D)

Department of Oncology, General University Hospital, Prague, Czech Republic.

Jaroslav Januška (J)

Cardiology, Podlesi Hospital Trinec, Czech Republic.

Jan Hecko (J)

Cardiology, Podlesi Hospital Trinec, Czech Republic.

Josef Kautzner (J)

Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH